-
1
-
-
24944577486
-
Alpha cell function in health and disease: influence of glucagon-like peptide-1
-
Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
-
(2005)
Diabetologia
, vol.48
, pp. 1700-1713
-
-
Dunning, B.E.1
Foley, J.E.2
Ahrén, B.3
-
2
-
-
0141446228
-
Enhancing incretin action for the treatment of type 2 diabetes
-
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
-
(2003)
Diabetes Care
, vol.26
, pp. 2929-2940
-
-
Drucker, D.J.1
-
3
-
-
84870054636
-
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
-
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 728-742
-
-
Meier, J.J.1
-
4
-
-
84874367468
-
Incretin therapy of type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors
-
Ahrén B. Incretin therapy of type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors. J Eur Diabet Nursing 2013; 10: 31-36.
-
(2013)
J Eur Diabet Nursing
, vol.10
, pp. 31-36
-
-
Ahrén, B.1
-
5
-
-
84859341109
-
Dipeptidyl peptidase-4 inhibitors: 3 years of experience
-
Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012; 14: 350-364.
-
(2012)
Diabetes Technol Ther
, vol.14
, pp. 350-364
-
-
Derosa, G.1
Maffioli, P.2
-
6
-
-
0021263283
-
Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions
-
Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 1984; 73: 1532-1541.
-
(1984)
J Clin Invest
, vol.73
, pp. 1532-1541
-
-
Bolli, G.B.1
Tsalikian, E.2
Haymond, M.W.3
Cryer, P.E.4
Gerich, J.E.5
-
7
-
-
84857401843
-
Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes
-
Cryer BE. Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012; 153: 1039-1048.
-
(2012)
Endocrinology
, vol.153
, pp. 1039-1048
-
-
Cryer, B.E.1
-
8
-
-
65249095686
-
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes
-
Ahrén B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 1236-1243
-
-
Ahrén, B.1
Schweizer, A.2
Dejager, S.3
-
9
-
-
34548118796
-
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes
-
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
-
(2007)
Diabet Med
, vol.24
, pp. 955-961
-
-
Schweizer, A.1
Couturier, A.2
Foley, J.E.3
Dejager, S.4
-
10
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
-
(2007)
Diabetes Care
, vol.30
, pp. 890-895
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
Rochotte, E.4
Garber, A.J.5
-
11
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
-
12
-
-
33846828660
-
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study
-
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study. Diabetes Obes Metab 2007; 9: 166-174.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 166-174
-
-
Garber, A.J.1
Schweizer, A.2
Baron, M.A.3
Rochotte, E.4
Dejager, S.5
-
13
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
-
14
-
-
4744363623
-
Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients type 1 and insulin-treated type 2 diabetes mellitus
-
Holstein A, Hammer C, Plachke A et al. Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients type 1 and insulin-treated type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004; 112: 429-434.
-
(2004)
Exp Clin Endocrinol Diabetes
, vol.112
, pp. 429-434
-
-
Holstein, A.1
Hammer, C.2
Plachke, A.3
-
15
-
-
84877633796
-
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
-
Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013; 15: 485-502.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 485-502
-
-
Balena, R.1
Hensley, I.E.2
Miller, S.3
Barnett, A.H.4
-
16
-
-
84879186130
-
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin
-
Schweizer A, Foley JE, Kothny W, Ahrén B. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag 2013; 9: 57-64.
-
(2013)
Vasc Health Risk Manag
, vol.9
, pp. 57-64
-
-
Schweizer, A.1
Foley, J.E.2
Kothny, W.3
Ahrén, B.4
-
17
-
-
84873873967
-
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
-
Kothny W, Foley J, Kozlovski P, Shao O, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 252-257.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 252-257
-
-
Kothny, W.1
Foley, J.2
Kozlovski, P.3
Shao, O.4
Gallwitz, B.5
Lukashevich, V.6
-
18
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
19
-
-
84873848407
-
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
-
Lukashevich V, Schweizer A, Foley JE, Fickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013; 9: 21-28.
-
(2013)
Vasc Health Risk Manag
, vol.9
, pp. 21-28
-
-
Lukashevich, V.1
Schweizer, A.2
Foley, J.E.3
Fickinson, S.4
Groop, P.H.5
Kothny, W.6
-
20
-
-
84882932426
-
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
-
Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013; 9: 155-163.
-
(2013)
Vasc Health Risk Manag
, vol.9
, pp. 155-163
-
-
Ahrén, B.1
-
21
-
-
84867238377
-
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes
-
Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 3799-3806.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 3799-3806
-
-
Farngren, J.1
Persson, M.2
Schweizer, A.3
Foley, J.E.4
Ahrén, B.5
-
22
-
-
23844463766
-
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
-
Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4888-4894
-
-
Mari, A.1
Sallas, W.M.2
He, Y.L.3
-
23
-
-
2442482515
-
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes
-
Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2078-2084
-
-
Ahrén, B.1
Landin-Olsson, M.2
Jansson, P.A.3
Svensson, M.4
Holmes, D.5
Schweizer, A.6
-
24
-
-
79961191559
-
Regulation of glucagon secretion by incretins
-
Holst JJ, Christensen M, Lund A et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011; 13(Suppl. 1): 89-94.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.SUPPL. 1
, pp. 89-94
-
-
Holst, J.J.1
Christensen, M.2
Lund, A.3
-
25
-
-
55649108863
-
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pâncreas
-
de Heer J, Rasmussen C, Coy D, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pâncreas. Diabetologia 2008; 51: 2263-2270.
-
(2008)
Diabetologia
, vol.51
, pp. 2263-2270
-
-
de Heer, J.1
Rasmussen, C.2
Coy, D.3
Holst, J.J.4
-
26
-
-
56049086867
-
Insulin as a physiological modulator of glucagon secretion
-
Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol 2008; 295: E751-E761.
-
(2008)
Am J Physiol
, vol.295
-
-
Bansal, P.1
Wang, Q.2
-
27
-
-
0036959991
-
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemia clamp experiments in healthy volunteers
-
Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemia clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 1239-1246
-
-
Nauck, M.A.1
Heimesaat, M.M.2
Behle, K.3
-
28
-
-
82255185915
-
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
-
Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 103-109.
-
(2011)
Diabetes
, vol.60
, pp. 103-109
-
-
Christensen, M.1
Vedtofte, L.2
Holst, J.J.3
Vilsbøll, T.4
Knop, F.K.5
-
29
-
-
0030936890
-
Activation of autonomic nervous and the adrenal medula contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women
-
Havel PJ, Ahrén B. Activation of autonomic nervous and the adrenal medula contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 1997; 46: 801-807.
-
(1997)
Diabetes
, vol.46
, pp. 801-807
-
-
Havel, P.J.1
Ahrén, B.2
-
30
-
-
84857401071
-
Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia
-
Taborsky GJ Jr, Mundinger TO. Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012; 153: 1055-1062.
-
(2012)
Endocrinology
, vol.153
, pp. 1055-1062
-
-
Taborsky Jr., G.J.1
Mundinger, T.O.2
-
31
-
-
0017948650
-
Vagal, cholinergic regulation of pancreatic polypeptide secretion
-
Schwartz TW, Holst JJ, Fahrenkrug J et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 1978; 61: 781-789.
-
(1978)
J Clin Invest
, vol.61
, pp. 781-789
-
-
Schwartz, T.W.1
Holst, J.J.2
Fahrenkrug, J.3
-
32
-
-
0030971354
-
The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in meditating glucagon release in normal humans
-
Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Heller SR. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in meditating glucagon release in normal humans. J Clin Endocrinol Metab 1997; 82: 1458-1461.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 1458-1461
-
-
Peacey, S.R.1
Rostami-Hodjegan, A.2
George, E.3
Tucker, G.T.4
Heller, S.R.5
-
33
-
-
0033304547
-
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes
-
Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3140-3146.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, pp. 3140-3146
-
-
Landstedt-Hallin, L.1
Adamson, U.2
Lins, P.E.3
-
34
-
-
79960831855
-
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
-
Ahrén B, Schweizer A, Dejager S, Villhauer ED, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13: 775-783.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 775-783
-
-
Ahrén, B.1
Schweizer, A.2
Dejager, S.3
Villhauer, E.D.4
Dunning, B.E.5
Foley, J.E.6
|